mani
patient
sever
lifethreaten
condit
endstag
organ
diseas
hematolog
malign
transplant
lifesav
modal
shift
toward
grow
age
popul
direct
impact
field
number
peopl
age
increas
age
year
increas
life
expect
older
individu
increas
gener
health
also
improv
direct
impact
age
popul
seen
transplant
popul
averag
age
patient
kidney
transplant
wait
list
increas
within
past
decad
seen
doubl
registr
age
year
old
age
year
older
also
increas
stark
contrast
declin
number
patient
younger
age
wait
list
trend
seen
kidney
transplant
su
et
al
report
mean
age
liver
transplant
registr
increas
year
proport
registr
age
year
older
increas
graft
surviv
data
older
individu
report
unit
network
organ
share
uno
also
shown
graft
surviv
similar
transplant
recipi
age
year
compar
age
less
year
respiratori
viral
infect
rvi
signific
caus
morbid
mortal
immunocompromis
patient
increas
number
elderli
patient
transplant
review
highlight
knowledg
transplant
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
recipi
infect
respiratori
virus
make
note
specif
impact
age
transplant
patient
preval
rvi
given
season
depend
combin
factor
method
exposur
type
circul
virus
virul
viru
detect
method
use
major
respiratori
viru
transmiss
occur
via
direct
contact
air
droplet
incub
period
rang
day
howev
virus
bocaviru
incub
period
still
unknown
one
studi
note
incid
rvi
sot
popul
episodespatientyear
driegh
et
al
evalu
epidemiolog
respiratori
virus
bronchoalveolar
lavag
bal
specimen
patient
lower
respiratori
tract
diseas
group
immunocompromis
adult
found
coronaviru
common
pathogen
found
follow
rhinoviru
respiratori
syncyti
viru
rsv
bocaviru
gener
studi
rvi
incid
transplant
popul
show
older
individu
similar
incid
rvi
acquisit
compar
younger
popul
within
sot
group
lung
transplant
recipi
appear
greatest
frequenc
rvi
develop
lower
airway
diseas
prospect
studi
lung
transplant
recipi
show
progress
rvi
involv
lower
respiratori
tract
occur
cohort
may
due
direct
contact
allograft
environ
immun
dysregul
within
allograft
potenti
greater
degre
immunosuppress
lung
transplant
compar
organ
transplant
type
studi
found
timedepend
associ
rvi
acut
reject
chronic
lung
allograft
dysfunct
clad
lung
transplant
popul
fisher
et
al
found
risk
clad
increas
month
follow
rvi
episod
similarli
studi
note
acut
reject
declin
forc
expiratori
volum
occur
patient
rvi
specif
studi
focus
epidemiolog
commun
respiratori
virus
allogen
hsct
patient
shown
rhinoviru
coronavirus
common
follow
adenoviru
rsv
fatal
rate
viral
pneumonia
report
anywher
amongst
hsct
popul
risk
factor
lower
respiratori
diseas
hsct
recipi
includ
older
age
greater
year
sever
neutropenia
sever
lymphopenia
myeloabl
condit
presenc
graft
versu
host
diseas
gvhd
cytomegaloviru
seroposit
clinic
present
similar
among
rvi
rhiniti
pharyng
malais
coryza
cough
common
symptom
presenc
fever
variabl
occur
depend
specif
rvi
use
reliabl
marker
chest
radiograph
find
lower
respiratori
tract
infect
nonspecif
includ
interstiti
diseas
consolid
small
pulmonari
nodul
case
lower
respiratori
infect
bacteri
superinfect
import
consid
respiratori
viru
posit
respiratori
specimen
gener
day
seri
howev
viru
remain
posit
sever
month
despit
resolut
symptom
one
studi
corticosteroid
dosag
greater
mgkg
daili
shown
prolong
influenza
viru
posit
compar
person
treat
lower
dose
vs
day
clinic
relev
prolong
shed
unknown
howev
seen
even
use
antivir
influenza
could
contribut
increas
risk
resist
virus
patient
suspect
rvi
nasopharyng
swab
wash
aspir
diagnosi
bal
specimen
also
use
detect
viral
cultur
histor
use
although
take
day
lead
delay
diagnosi
addit
cultur
method
avail
respiratori
virus
direct
fluoresc
antibodi
dfa
provid
result
hour
reagent
avail
limit
number
virus
influenza
b
parainfluenza
rsv
adenoviru
dfa
also
requir
presenc
epitheli
cell
higher
sensit
requir
technic
expertis
interpret
result
sensit
dfa
rang
rapid
antigen
detect
assay
primarili
use
influenza
rsv
diagnosi
howev
new
gold
standard
test
multiplex
nucleic
acid
test
nat
abil
detect
divers
number
respiratori
virus
result
avail
within
h
sensit
multiplex
nat
assay
rang
best
sensit
seen
influenza
lower
sensit
adenoviru
parainfluenza
inactiv
influenza
vaccin
wide
recommend
prevent
infect
transplant
candid
recipi
close
contact
healthcar
worker
recent
year
trival
formul
avail
contain
two
one
b
strain
howev
given
frequent
cocircul
second
b
strain
quadrival
vaccin
develop
immunogen
influenza
vaccin
depend
type
transplant
popul
studi
immunosuppress
time
transplant
lung
transplant
recipi
gener
lower
immunogen
organ
transplant
type
higher
dose
mycophenol
mofetil
shown
inhibit
influenza
vaccin
immunogen
vaccin
immunogen
lowest
first
month
sot
guidelin
gener
suggest
immun
patient
start
month
posttranspl
howev
start
earli
month
posttranspl
also
suggest
earli
posttranspl
vaccin
may
immunogen
especi
consid
pandem
outbreak
situat
hsct
recipi
influenza
vaccin
poor
immunogen
first
month
posttranspl
mani
center
delay
vaccin
time
variou
type
inactiv
influenza
vaccin
avail
unadjuv
vaccin
adjuv
vaccin
highdos
vaccin
seroconvers
seroprotect
rate
nonadjuv
standard
dose
vaccin
rang
transplant
recipi
factor
influenc
variabl
includ
type
transplant
time
transplant
immunosuppress
well
presenc
gvhd
allogen
hsct
one
studi
investig
use
novel
highdos
intraderm
id
show
use
mycophenol
mofetil
invers
associ
vaccin
respons
dosedepend
manner
contrari
gener
popul
age
tradit
factor
impact
standard
influenza
vaccin
respons
transplant
recipi
potenti
impact
immunosuppress
medic
supersed
impact
age
variou
strategi
improv
influenza
vaccin
respons
studi
transplant
popul
administ
two
dose
vaccin
season
appear
margin
benefit
sot
recipi
signific
benefit
allogen
hsct
influenza
vaccin
also
avail
shown
promis
popul
year
age
oilinwat
emuls
work
local
attract
inflammatori
cell
site
inject
random
trial
influenza
vaccin
kidney
transplant
show
vaccin
similar
immunogen
unadjuv
vaccin
studi
person
age
year
significantli
diminish
vaccin
immunogen
group
exclud
analysi
subgroup
analysi
patient
age
year
show
adjuv
vaccin
perform
better
standard
vaccin
adult
allogen
hsct
patient
anoth
random
control
trial
use
done
natori
et
al
also
found
adjuv
vaccin
demonstr
similar
immunogen
nonadjuv
vaccin
highdos
vaccin
contain
four
time
antigen
standard
dose
vaccin
also
author
person
age
year
vaccin
shown
improv
immunogen
cohort
hsct
transplant
recipi
well
pediatr
organ
transplant
recipi
trial
highdos
vaccin
adult
sot
recipi
underway
rsv
also
lead
caus
rvi
caus
sever
diseas
transplant
recipi
hsct
recipi
incid
lower
respiratori
infect
mortal
risk
factor
progress
infect
lower
respiratori
tract
includ
degre
immunosuppress
presenc
neutropenia
lymphopenia
gvhd
waghmar
et
al
show
older
age
associ
rsv
mortal
multivari
analysi
sot
group
lung
transplant
recipi
greatest
risk
lower
respiratori
tract
diseas
rsv
infect
along
commun
acquir
rvi
risk
acut
reject
clad
lung
transplant
recipi
ribavirin
mainstay
treatment
rsv
infect
given
aerosol
oral
intraven
formul
survey
done
rsv
treatment
us
organ
transplant
center
show
ribavirin
use
center
lung
transplant
recipi
lower
respiratori
tract
rsv
infect
practic
rsv
upper
lower
tract
infect
nonlung
recipi
variabl
nebul
form
ribavirin
given
via
small
particl
aerosol
gener
spag
unit
dosag
g
everi
h
one
dose
g
h
aerosol
ribavirin
teratogen
requir
neg
pressur
room
small
random
studi
hsct
patient
rsv
show
decreas
viral
load
time
effect
develop
pneumonia
subsequ
retrospect
review
hsct
recipi
infect
rsv
demonstr
ribavirin
therapi
reduc
risk
lower
respiratori
tract
infect
rsvassoci
mortal
oral
ribavirin
also
use
small
case
seri
hsct
recipi
gorcea
et
al
treat
rsvposit
patient
oral
ribavirin
median
day
note
one
rsvrelat
death
intraven
immunoglobulin
palivizumab
shown
benefit
hsct
set
immunodefici
score
index
determin
riskbas
ribavirin
therapi
hsct
recipi
suggest
lung
transplant
recipi
aerosol
oral
ribavirin
use
burrow
et
al
report
episod
rsv
lung
transplant
recipi
treat
intraven
ribavirin
load
mgkg
dose
follow
oral
ribavirin
mgkgday
median
day
although
untreat
control
bronchiol
obliteran
develop
patient
anemia
worsen
half
patient
smaller
studi
lung
transplant
recipi
show
signific
differ
clinic
outcom
receiv
oral
versu
aerosol
ribavirin
aggress
protocol
use
includ
aerosol
ribavirin
methylprednisolon
intraven
immunoglobulin
palivizumab
contrari
good
outcom
observ
alon
also
seen
lung
transplant
patient
rsv
therefor
consensu
whether
treat
lung
transplant
recipi
rsv
upper
tract
infect
taken
togeth
data
ribavirin
involv
retrospect
case
seri
mani
limit
sampl
size
andor
inadequ
power
show
differ
therapi
may
also
report
bia
literatur
therefor
firm
conclus
drawn
regard
effect
ribavirin
treatment
rsv
newer
therapi
develop
rsv
includ
inhal
small
interf
rna
sirna
shown
prevent
bronchiol
obliteran
random
trial
lung
transplant
recipi
rsv
fusion
inhibitor
monoclon
antibodi
direct
fusion
protein
rsv
shown
promis
earli
trial
may
form
futur
therapi
transplant
recipi
multipl
rsv
vaccin
candid
develop
potenti
studi
transplant
popul
piv
singlestrand
envelop
rna
virus
paramyovirida
famili
piv
compris
group
four
serotyp
serotyp
tend
occur
sporad
fall
winter
month
mild
environ
type
occur
year
common
type
caus
outbreak
among
hsct
organ
transplant
recipi
type
less
common
epidemiolog
studi
similar
respiratori
virus
piv
associ
sever
lower
respiratori
tract
infect
transplant
patient
one
studi
leukemia
hsct
patient
piv
mortal
lower
respiratori
tract
infect
trend
greater
piv
pneumonia
year
p
compar
younger
patient
systemat
review
found
gvhd
risk
factor
acquisit
piv
infect
lower
respiratori
infect
lymphopenia
neutropenia
steroid
use
also
predict
lower
respiratori
infect
piv
current
support
care
mainstay
treatment
piv
infect
studi
shown
ribavirin
benefici
therapi
piv
hsct
patient
experi
ribavirin
piv
infect
organ
transplant
recipi
limit
similar
influenza
piv
also
bind
sialic
acid
host
epitheli
cell
inhal
sialidas
fusion
protein
inhibitor
shown
promis
result
treatment
piv
immunocompromis
patient
waghmar
et
al
use
treat
piv
diseas
four
pediatr
patient
immunocompromis
patient
toler
drug
well
improv
viral
load
symptom
initi
therapi
observ
may
option
treat
piv
transplant
recipi
futur
adenoviru
produc
wide
array
clinic
symptom
transplant
patient
nonenvelop
doublestrand
dna
viru
immunolog
uniqu
serotyp
classifi
subgroup
f
adenoviru
establish
lifelong
asymptomat
infect
lymphoid
tissu
suggest
adenoviru
diseas
may
occur
reactiv
latent
infect
rather
de
novo
infect
de
novo
infect
incub
period
rang
day
week
depend
serotyp
transplant
popul
incid
rate
rang
hsct
recipi
sot
recipi
clinic
present
nonspecif
includ
upper
respiratori
tract
symptom
conjunct
fever
enter
hepat
enceph
mortal
rate
relat
adenoviru
pneumonia
hepat
one
prospect
studi
sot
recipi
adenoviru
found
patient
throughout
first
year
posttranspl
studi
older
age
factor
develop
viremia
major
patient
asymptomat
though
respiratori
gastrointestin
symptom
none
patient
adenovirusdirect
therapi
seriou
sequela
observ
kidney
transplant
recipi
adenoviru
may
caus
pyelonephr
lung
transplant
recipi
adenoviru
associ
graft
loss
death
progress
oblit
bronchiol
diagnosi
made
serolog
nat
cultur
polymeras
chain
reaction
pcr
situ
hybrid
immunochemistri
establish
therapi
adenoviru
although
small
case
seri
dissemin
adenoviru
sot
recipi
document
success
treatment
use
cidofovir
adjunct
intraven
immunoglobulin
reduct
immunosuppress
appear
import
intervent
organ
transplant
recipi
dissemin
diseas
allogen
hsct
recipi
hemorrhag
cystiti
adenoviru
shown
improv
intravesicular
instil
cidofovir
brincidofovir
remain
investig
compound
vitro
activ
dna
virus
includ
adenoviru
case
seri
document
success
outcom
adenovirusspecif
cell
emerg
therapi
futur
due
histor
limit
diagnost
test
specif
human
coronaviru
hcov
incid
transplant
recipi
like
underestim
howev
develop
nat
strain
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
seen
affect
transplant
patient
respiratori
virus
symptom
nonspecif
includ
fever
myalgia
cough
dyspnea
characterist
laboratori
marker
includ
lymphopenia
thrombocytopenia
elev
lactat
dehydrogenas
viral
pneumon
may
evid
chest
radiograph
new
coronaviru
caus
sar
emerg
common
present
symptom
includ
fever
chill
headach
malais
nonproduct
cough
dyspnea
lower
respiratori
tract
infect
common
mortal
approxim
lymphopenia
elev
lactat
dehydrogenas
level
elev
creatinin
kinas
level
seen
patient
afflict
sar
advanc
age
risk
factor
advers
outcom
sar
odd
ratio
per
decad
life
sar
distinctli
link
exposur
healthcar
set
liver
transplant
patient
develop
sar
like
expos
outpati
podiatri
appoint
day
prior
present
patient
treat
intraven
ribavirin
ceftriaxon
azithromycin
succumb
ill
merscov
rel
new
coronaviru
identifi
june
mortal
rate
immunocompet
person
http
wwwwhointmediacentrefactsheetsmerscoven
two
microbiolog
document
merscov
case
report
renal
transplant
recipi
patient
present
fatigu
dyspnea
well
fever
one
case
one
patient
treat
ribavirin
pegyl
interferon
succumb
diseas
patient
receiv
support
care
recov
specif
target
therapi
hcov
ribavirin
use
treatment
sar
observ
studi
intraven
ribavirin
treatment
sar
indic
improv
major
patient
although
patient
signific
toxic
includ
hemolysi
patient
interferonalpha
also
use
potenti
immunomodulatori
therapi
sar
limit
effect
adjunct
corticosteroid
show
benefit
random
trial
regard
reduc
mortal
human
metapneumoviru
hmpv
rel
newer
paramyxoviru
close
relat
rsv
caus
upper
sever
lower
respiratori
tract
infect
transplant
englund
et
al
document
associ
hmpv
respiratori
failur
septic
shocklik
present
death
acut
respiratori
failur
occur
hsct
recipi
progress
lower
respiratori
tract
occur
hsct
recipi
especi
lymphopenia
system
corticosteroid
older
age
identifi
risk
factor
progress
studi
lung
transplant
recipi
infect
hmpv
associ
graft
dysfunct
treatment
consist
support
care
reduct
immunosuppress
use
ribavirin
also
studi
although
effect
difficult
assess
lack
control
rhinoviru
b
c
circul
yearround
common
caus
upper
respiratori
tract
infect
transplant
recipi
variou
studi
signific
rhinoviru
current
unclear
although
may
found
coinfect
mani
patient
report
suggest
lower
respiratori
tract
infect
rhinoviru
occur
hsct
recipi
mortal
seo
et
al
show
patient
lower
respiratori
infect
rhinoviru
year
age
greater
viral
load
rhinoviru
tend
correl
symptom
prolong
shed
occur
ki
wu
polyomavirus
also
recent
discov
report
predominantli
pediatr
hsct
popul
one
studi
kidney
transplant
patient
found
ki
respiratori
plasma
urin
specimen
respect
similarli
wu
found
respiratori
plasma
specimen
respect
clinic
consequ
infect
yet
defin
bocavirus
parvovirus
also
note
sever
studi
respiratori
viru
infect
transplant
recipi
howev
signific
clinic
consequ
report
manag
virus
transplant
recipi
consist
close
observ
support
therapi
nosocomi
infect
associ
commun
respiratori
virus
lead
devast
diseas
immunocompromis
patient
prevent
transmiss
includ
gener
infect
control
measur
singleroom
isol
droplet
precaut
screen
restrict
visitor
respiratori
symptom
ask
symptomat
hospit
staff
avoid
immunocompromis
patient
precaut
adher
virul
virus
pandem
influenza
strain
newer
coronavirus
high
mortal
fit
test
mask
neg
pressur
isol
might
requir
outbreak
occur
transplant
unit
hospit
may
want
consid
temporari
hold
perform
new
transplant
discharg
patient
admit
investig
elect
procedur
daili
screen
staff
symptom
respiratori
ill
send
ill
staff
home
promptli
minim
outpati
appoint
procedur
influenza
infect
outbreak
transplant
ward
inpati
offer
chemoprophylaxi
avail
close
contact
transplant
patient
vaccin
due
advanc
treatment
endstag
organ
diseas
hematolog
malign
transplant
offer
older
individu
respiratori
virus
continu
import
caus
morbid
mortal
transplant
commun
use
molecular
diagnost
wider
array
virus
detect
although
specif
therapi
avail
rvi
specif
data
respiratori
virus
older
transplant
recipi
lack
howev
larg
cohort
studi
show
mani
respiratori
virus
appear
caus
sever
diseas
advanc
age
influenza
import
prevent
older
transplant
patient
vaccin
key
prevent
standard
inactiv
influenza
vaccin
poor
immunogen
especi
older
transplant
patient
newer
vaccin
strategi
need
rsv
caus
sever
lower
respiratori
diseas
controversi
exist
effect
differ
formul
ribavirin
rvi
support
care
primari
manag
given
import
clinic
consequ
older
transplant
popul
import
develop
new
antivir
vaccin
prevent
morbid
mortal
